NT-003
In-house R&D- Research area / Indication
- IgA nephropathy, FSGS
- Territory
- Global
- Positioning
- Dual-target inhibitor with high technical complexity
- Market potential
- Market potential above 1 billion
PRODUCTS
Explore NICOYA products, regional progress and partnerships.
OUR PIPELINE
In-house and in-licensed programs focused on kidney disease.
| Origin | Program | Research area / Indication | Territory | Positioning and market potential | Preclinical | IND | Phase I / II | Phase III | NDA / BLA |
|---|---|---|---|---|---|---|---|---|---|
| In-house R&D | NT-003 | IgA nephropathy, FSGS | Global | Dual-target inhibitor with high technical complexity Market potential above 1 billion | |||||
| NT-004 | Diabetic kidney disease, hypertension and other indications | Global | Differentiated established target with limited competition; potential for breakthrough therapy in selected diseases Market potential above 1 billion | ||||||
| NT-007 | Diabetic kidney disease and other indications | Global | Dual antagonist with first-in-class potential Billion-scale market potential | ||||||
| In-licensed | NT-002 · RAYALDEE | CKD-related vitamin D deficiency and secondary hyperparathyroidism | Greater China | A first-in-class product with high technical barriers, addressing unmet needs Billion-scale market potential | Approved overseas; mainland China registration progressingMacao approval in November 2024; China phase III completed and pre-NDA dialogue submitted in April 2025; mainland China approval expected around 2026 | ||||
Preclinical · IND · Phase I / II · Phase III · NDA / BLA
Macao approval in November 2024; China phase III completed and pre-NDA dialogue submitted in April 2025; mainland China approval expected around 2026
Unmet needs in nephrology guide a portfolio spanning early research, clinical development and registration.
Research indications are not approved indications. Market potential and registration targets are forward-looking, not guarantees of performance, clinical success or approval. Partnership interests are distinct from active development.
Calcifediol extended-release capsules
An extended-release formulation of calcifediol and a key product in NICOYA's regional collaboration with OPKO.
Find product labeling, regional information and guidance on using website materials.